Bone markers and current laboratory assays

被引:21
作者
Hannon, RA [1 ]
Eastell, R [1 ]
机构
[1] Univ Sheffield, Acad Unit Bone Metab, Div Clin Sci N, Ctr Clin Sci,No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England
关键词
metastatic bone disease; bone marker assays; bone resorption; bone formation; NTX; CTX; ICTP;
D O I
10.1016/S0305-7372(06)80003-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastasis of cancer to bone leads to significant alterations in normal bone remodelling that are reflected in changes in bone turnover markers. These markers are classically defined as markers of bone resorption or formation; markers of bone resorption are measures of osteoclastic activity, whereas markers of bone formation are measures of osteoclastic activity. Recently, there has been growing interest in the use of these markers in metastatic bone disease (MBD), and an increasing number of studies have investigated the potential use of these markers in diagnosis, monitoring of disease progression and treatment, and prediction of outcome. In this review, we briefly discuss the biology of bone metastases as well as describe the bone turnover markers and their possible role in aiding clinicians in the treatment of patients with MBD. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7 / 14
页数:8
相关论文
共 79 条
[1]   Serum markers of bone metabolism in multiple myeloma: Prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP) [J].
Abildgaard, N ;
Bentzen, SM ;
Nielsen, JL ;
Heickendorff, L .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 96 (01) :103-110
[2]   Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy [J].
Abildgaard, N ;
Brixen, K ;
Kristensen, JE ;
Eriksen, EF ;
Nielsen, JL ;
Heickendorff, L .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (02) :235-242
[3]  
Al-Dehaimi AW, 1999, CLIN CHEM, V45, P676
[4]   Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (Type II autosomal dominant osteopetrosis) [J].
Alatalo, SL ;
Ivaska, KK ;
Waguespack, SG ;
Econs, MJ ;
Väänänen, HK ;
Halleen, JM .
CLINICAL CHEMISTRY, 2004, 50 (05) :883-890
[5]   Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone [J].
Alexandersen, P ;
Peris, P ;
Guañabens, N ;
Byrjalsen, I ;
Alvarez, L ;
Solberg, H ;
Cloos, PAC .
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (04) :588-595
[6]   Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients [J].
Alexandrakis, MG ;
Passam, FH ;
Malliaraki, N ;
Katachanakis, C ;
Kyriakou, DS ;
Margioris, AN .
CLINICA CHIMICA ACTA, 2002, 325 (1-2) :51-57
[7]   Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone [J].
Apone, S ;
Lee, MY ;
Eyre, DR .
BONE, 1997, 21 (02) :129-136
[8]   Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer [J].
Aruga, A ;
Koizumi, M ;
Hotta, R ;
Takahashi, S ;
Ogata, E .
BRITISH JOURNAL OF CANCER, 1997, 76 (06) :760-764
[9]   Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases [J].
Berruti, A ;
Dogliotti, L ;
Tucci, M ;
Tarabuzzi, R ;
Guercio, S ;
Torta, M ;
Tampellini, M ;
Dovio, A ;
Poggio, M ;
Scarpa, RM ;
Angeli, A .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2002, 17 (04) :244-252
[10]   Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline [J].
Berruti, A ;
Dogliotti, L ;
Bitossi, R ;
Fasolis, G ;
Gorzegno, G ;
Bellina, M ;
Torta, M ;
Porpiglia, F ;
Fontana, D ;
Angeli, A .
JOURNAL OF UROLOGY, 2000, 164 (04) :1248-1253